152 related articles for article (PubMed ID: 19760629)
1. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Isahaya E; Hara N; Nishiyama T; Hoshii T; Takizawa I; Takahashi K
Prostate; 2010 Feb; 70(2):155-61. PubMed ID: 19760629
[TBL] [Abstract][Full Text] [Related]
2. Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.
Hara N; Nishiyama T; Takizawa I; Saito T; Kitamura Y; Takahashi K
Urology; 2010 Jun; 75(6):1441-5. PubMed ID: 20110105
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
5. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu.
Takizawa I; Nishiyama T; Hara N; Isahaya E; Hoshii T; Takahashi K
Prostate; 2010 Sep; 70(13):1395-401. PubMed ID: 20687212
[TBL] [Abstract][Full Text] [Related]
7. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
8. Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.
Takizawa I; Hara N; Nishiyama T; Isahaya E; Hoshii T; Takahashi K
J Urol; 2010 Nov; 184(5):1971-6. PubMed ID: 20884032
[TBL] [Abstract][Full Text] [Related]
9. Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.
Satoh T; Kimura M; Matsumoto K; Tabata K; Okusa H; Bessho H; Iwamura M; Ishiyama H; Hayakawa K; Baba S
Cancer; 2009 Aug; 115(15):3468-74. PubMed ID: 19484786
[TBL] [Abstract][Full Text] [Related]
10. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
[TBL] [Abstract][Full Text] [Related]
11. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
[TBL] [Abstract][Full Text] [Related]
12. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
14. Effect of androgen deprivation therapy on bone mineral density in prostate cancer patients.
Deng JH; Yang LP; Wang LS; Zhou DF
Asian J Androl; 2004 Mar; 6(1):75-7. PubMed ID: 15064839
[TBL] [Abstract][Full Text] [Related]
15. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
Wadhwa VK; Weston R; Mistry R; Parr NJ
BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
[TBL] [Abstract][Full Text] [Related]
17. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
Wilcox A; Carnes ML; Moon TD; Tobias R; Baade H; Stamos E; Elliott ME
Ann Pharmacother; 2006 Dec; 40(12):2107-14. PubMed ID: 17132807
[TBL] [Abstract][Full Text] [Related]
19. Oral bisphosphonate prevents bone loss in androgen deprivation therapy for nonmetastatic prostate cancer.
Kawahara T; Kobayashi T; Nishizawa K; Kobori G; Mitsumori K; Ogura K
Hinyokika Kiyo; 2008 Apr; 54(4):261-6. PubMed ID: 18516917
[TBL] [Abstract][Full Text] [Related]
20. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
